Learn peptides step by step

Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means

Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.

Amylin and GLP-1: The Next Wave of Metabolic Peptides

The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.

Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data

The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.

Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch

Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.

Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide

The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.

Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means

31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.

Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard

New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.

ProtocolsIntermediate

Switching from Tirzepatide to Retatrutide: The Complete Transition Guide

Already on tirzepatide and considering retatrutide? Here's exactly how to make the switch—starting doses based on your current Tirz level, what the glucagon component changes, and how to avoid common transition mistakes.

ProtocolsIntermediate

Retatrutide Dosing for Beginners: Your First 12-Week Titration Schedule

Retatrutide is one of the most powerful GLP-1/GIP/glucagon receptor agonists available. But starting at the wrong dose — or jumping up too fast — is the #1 beginner mistake. Here's the complete titration roadmap.

Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss

Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.

Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard

Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.

The Science of Retatrutide: How GLP-1/GIP/Glucagon Triple Agonists Work

Retatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.

How Retatrutide Works: The Science Behind the Triple-Receptor Agonist

Retatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.

Why Retatrutide Preserves Muscle Better Than Tirzepatide

Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.

Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial

Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.

Retatrutide: The Triple-Action Weight Loss Peptide Explained

Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.